Ce. Begley et al., The cost of epilepsy in the United States: An estimate from population-based clinical and survey data, EPILEPSIA, 41(3), 2000, pp. 342-351
Purpose: To provide 1995 estimates of the lifetime and annual cost of epile
psy in the United States using data from patients with epilepsy, and adjust
ing for the effects of comorbidities and socioeconomic conditions.
Methods: Direct treatment-related costs of epilepsy from onset through 6 ye
ars were derived from billing and medical chart data for 608 population-bas
ed incident cases at two sites in different regions of the country. Indirec
t productivity-related costs were derived from a survey of 1,168 adult pati
ents visiting regional treatment centers. Direct costs separate the effects
of epilepsy and comorbidity conditions. Indirect costs account for the eff
ects of other disabilities and socioeconomic conditions on foregone earning
s and household activity. The estimates were applied to 1995 population fig
ures to derive national projections of the lifetime and annual costs of the
disorder.
Results: The lifetime cost of epilepsy for an estimated 181,000 people with
onset in 1995 is projected at $11.1 billion, and the annual cost for the e
stimated 2.3 million prevalent cases is estimated at $12.5 billion. Indirec
t costs account for 85% of the total and, with direct costs, are concentrat
ed in people with intractable epilepsy.
Conclusions: Direct coats attributable to epilepsy are below previous estim
ates. Indirect costs adjusted for the socioeconomic conditions of patients
are above previous estimates. Findings indicate that epilepsy is unique in
the large proportion of costs that are productivity-related, justifying fur
ther investment in the development of effective interventions.